4/17
07:52 am
eras
Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class' Potential of Cancer Treatment [Yahoo! Finance]
Low
Report
Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class' Potential of Cancer Treatment [Yahoo! Finance]
4/9
05:57 pm
eras
What's Driving Erasca (ERAS)'s Nearly 355% YTD Return [Yahoo! Finance]
Low
Report
What's Driving Erasca (ERAS)'s Nearly 355% YTD Return [Yahoo! Finance]
4/6
05:38 pm
eras
Erasca (ERAS) Among the Best Performing Stocks of Q1 2026 to Watch for Q2 [Yahoo! Finance]
Low
Report
Erasca (ERAS) Among the Best Performing Stocks of Q1 2026 to Watch for Q2 [Yahoo! Finance]
3/26
06:17 pm
eras
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't [Yahoo! Finance]
Medium
Report
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't [Yahoo! Finance]
3/23
08:26 am
eras
Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation [Yahoo! Finance]
Medium
Report
Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation [Yahoo! Finance]
3/20
03:42 am
eras
Erasca (ERAS) Adds 13%; Soars 310% YTD [Yahoo! Finance]
Medium
Report
Erasca (ERAS) Adds 13%; Soars 310% YTD [Yahoo! Finance]
3/18
11:48 am
eras
Erasca (ERAS) had its price target raised by JPMorgan Chase & Co. from $24.00 to $25.00. They now have an "overweight" rating on the stock.
Low
Report
Erasca (ERAS) had its price target raised by JPMorgan Chase & Co. from $24.00 to $25.00. They now have an "overweight" rating on the stock.
3/16
09:16 am
eras
Erasca (ERAS) had its price target raised by Guggenheim from $12.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Erasca (ERAS) had its price target raised by Guggenheim from $12.00 to $20.00. They now have a "buy" rating on the stock.
3/13
01:06 pm
eras
Erasca (ERAS) had its price target raised by Piper Sandler from $11.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
Erasca (ERAS) had its price target raised by Piper Sandler from $11.00 to $18.00. They now have an "overweight" rating on the stock.
3/12
04:57 pm
eras
Erasca GAAP EPS of -$0.19 [Seeking Alpha]
Medium
Report
Erasca GAAP EPS of -$0.19 [Seeking Alpha]
3/12
04:01 pm
eras
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Medium
Report
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
3/10
07:01 pm
eras
Erasca (ERAS) was given a new $20.00 price target by Stifel Nicolaus.
Low
Report
Erasca (ERAS) was given a new $20.00 price target by Stifel Nicolaus.
3/10
08:00 am
eras
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Low
Report
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
3/9
11:23 am
eras
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts [Yahoo! Finance]
Low
Report
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts [Yahoo! Finance]
3/9
10:35 am
eras
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango's Dual-Target Trial Collaboration? [Yahoo! Finance]
Medium
Report
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango's Dual-Target Trial Collaboration? [Yahoo! Finance]
3/5
01:50 pm
eras
Tango rises after Q4 results, clinical pact with Erasca [Seeking Alpha]
Low
Report
Tango rises after Q4 results, clinical pact with Erasca [Seeking Alpha]
3/5
07:41 am
eras
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
Low
Report
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
3/5
07:13 am
eras
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat [Yahoo! Finance]
Low
Report
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat [Yahoo! Finance]
3/5
07:01 am
eras
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
Low
Report
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
3/2
04:22 pm
eras
Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
2/28
07:02 pm
eras
Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 [Yahoo! Finance]
Medium
Report
Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 [Yahoo! Finance]
2/28
03:22 pm
eras
Erasca, Inc. (ERAS): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Erasca, Inc. (ERAS): A Bull Case Theory [Yahoo! Finance]
2/24
08:00 am
eras
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
Medium
Report
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
2/5
08:15 am
eras
Erasca to Present at Upcoming Conferences in February [Yahoo! Finance]
Medium
Report
Erasca to Present at Upcoming Conferences in February [Yahoo! Finance]
2/5
08:00 am
eras
Erasca to Present at Upcoming Conferences in February
Medium
Report
Erasca to Present at Upcoming Conferences in February